The impacts of continuous veno-venous hemofiltration on plasma cytokines and monocyte human leukocyte antigen-DR expression in septic patients

被引:52
作者
Zhang Peng [1 ]
Peng Pai [2 ]
Liu Hong-Bao [1 ]
Li Rong [1 ]
Wang Han-Min [1 ]
Huang Chen [1 ]
机构
[1] Fourth Mil Med Univ, Dept Nephrol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China
[2] Fourth Mil Med Univ, Inst Plast Surg, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China
关键词
Sepsis; Continuous veno-venous hemofiltration; Monocyte human leukocyte antigen; Cytokine; RENAL REPLACEMENT THERAPY; MONOCLONAL-ANTIBODY; ORGAN FAILURE; SEVERE SEPSIS; DOUBLE-BLIND; SHOCK; INTERLEUKIN-10; REMOVAL; ALPHA;
D O I
10.1016/j.cyto.2010.02.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aim of this study was to investigate the impacts of continuous veno-venous hemofiltration (CVVH) on plasma cytokines and monocyte human leukocyte antigen-DR (HLA-DR) expression and to evaluate the relationship between them during CVVH treatment in septic patients. Forty septic patients were enrolled in this study. They were randomly divided into control group (who received conventional treatment, n = 20) and CVVH group (who received conventional treatment and CVVH treatment, n = 20). The blood samples were taken to measure the changes of plasma cytokines (IFN-gamma, TNF-alpha, IL-1, IL-2, IL-4, IL-6, IL-10 and IL-13) and HLA-DR expression on monocytes. After CVVH treatment, the plasma levels of IFN-gamma, IL-1, IL-2, IL-4, IL-10 and IL-13 in septic patients were markedly decreased (P<0.05), while the levels of TNF-alpha and IL-6 were only lowered to some extent without significant difference (P>0.05). HLA-DR expression on monocytes improved in CVVH treated patients (P<0.05). No matter pre-treatment or post-treatment of CVVH, there was a negative correlation between plasma IL-10 and monocyte HLA-DR expression (P<0.05). In contrast, no obvious change was shown in control patients. Our findings suggest that CVVH is effective in removal of many plasma cytokines and in improvement of monocyte HLA-DR expression in septic patients. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:186 / 191
页数:6
相关论文
共 26 条
  • [1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL
    ABRAHAM, E
    WUNDERINK, R
    SILVERMAN, H
    PERL, TM
    NASRAWAY, S
    LEVY, H
    BONE, R
    WENZEL, RP
    BALK, R
    ALLRED, R
    PENNINGTON, JE
    WHERRY, JC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941
  • [2] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [3] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [4] BROWN A, 1991, Journal of the American Society of Nephrology, V2, P316
  • [5] Cytokine removal during continuous renal replacement therapy:: An ex vivo comparison of convection and diffusion
    Cole, L
    Bellomo, R
    Davenport, P
    Tipping, P
    Ronco, C
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2004, 27 (05) : 388 - 397
  • [6] HLA-DR expression and soluble HLA-DR levels in septic patients after trauma
    Ditschkowski, M
    Kreuzfelder, E
    Rebmann, V
    Ferencik, S
    Majetschak, M
    Schmid, EN
    Obertacke, U
    Hirche, H
    Schade, UF
    Grosse-Wilde, H
    [J]. ANNALS OF SURGERY, 1999, 229 (02) : 246 - 254
  • [7] Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice
    Echtenacher, B
    Weigl, K
    Lehn, N
    Männel, DN
    [J]. INFECTION AND IMMUNITY, 2001, 69 (06) : 3550 - 3555
  • [8] ESKANDARI MK, 1992, J IMMUNOL, V148, P2724
  • [9] Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein
    Fisher, CJ
    Agosti, JM
    Opal, SM
    Lowry, SF
    Balk, RA
    Sadoff, JC
    Abraham, E
    Schein, RMH
    Benjamin, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) : 1697 - 1702
  • [10] Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options
    Gogos, CA
    Drosou, E
    Bassaris, HP
    Skoutelis, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) : 176 - 180